Hong Kong Stock Welcomes First Synthetic Lethality Cancer Drug Leader, Share Price Surges Over 117%

British Pharmaceutical (7630.HK), focusing on synthetic lethality precise anti-cancer therapy, debuted on the main board of the Hong Kong Stock Exchange. The company is the first in the Hong Kong stock market to focus on the synthetic lethality track and achieve commercialization of its core product, a Biotech cancer drug. With a global offering of 41.977 million shares at a price of HK$20.1, the total fundraising amounted to approximately HK$844 million. On its first day of trading, British Pharmaceutical opened at HK$34.2 per share, a 70.15% increase from the offering price, resulting in a market value of HK$9.445 billion. By…